Loading…
Glenmark Pharmaceuticals (GLENMARK)₹2,671+2.94%Pharmaceuticals
At the end of the Jun 2026 quarter, Glenmark Pharmaceuticals' shareholders were: promoters 46.61%, FIIs 20.91%, DIIs 18.58%, government 0.04%, public 13.86%. Promoter holding is unchanged on the quarter. FII holding is up 0.27 percentage points from 20.64% a year earlier. 0.00% of promoter shares were pledged. It had 2,11,396 shareholders.
As of · Company filings (shareholding pattern)
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 46.61% | 46.61% | 46.61% | 46.61% | 46.61% | 46.61% | 46.61% | 46.60% | 46.60% | 46.61% | 46.61% | 46.61% |
| FIIs | 24.81% | 23.73% | 21.40% | 21.00% | 23.07% | 23.53% | 23.17% | 20.64% | 20.75% | 19.22% | 20.37% | 20.91% |
| DIIs | 10.29% | 10.90% | 13.34% | 13.91% | 13.19% | 13.83% | 14.58% | 17.62% | 18.59% | 20.07% | 19.26% | 18.58% |
| Government | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% |
| Public | 18.25% | 18.72% | 18.61% | 18.44% | 17.09% | 15.99% | 15.60% | 15.10% | 14.02% | 14.06% | 13.72% | 13.86% |
| Promoter shares pledged | — | — | — | — | — | — | — | — | — | — | — | 0.00% |
| Number of shareholders | 2,32,661 | 2,09,909 | 1,99,430 | 1,92,610 | 1,93,929 | 1,95,039 | 1,92,704 | 1,90,190 | 1,98,768 | 2,01,563 | 1,96,085 | 2,11,396 |
| Holder | Category | Jun 2026 | Change (pp) |
|---|---|---|---|
| Saldanha Family Trust | Promoter | 45.41% | 0.00 |
| Hdfc Mutual Fund - Hdfc Mid-Cap Fund | DII | 6.18% | New |
| Government Pension Fund Global | FII | 3.92% | +0.11 |
| Amansa Holdings Private Limited | FII | 2.20% | 0.00 |
| Invesco India Contra Fund | DII | 2.19% | New |
| Bandhan Nifty 200 Momentum 30 Index Fund | DII | 1.27% | New |
| Uti Multi Cap Fund | DII | 1.16% | New |
| Blanche Elizabeth Saldanha | Promoter | 0.39% | 0.00 |
| Glenn Mario Saldanha | Promoter | 0.36% | 0.00 |
| Cherylann Maria Pinto | Promoter | 0.27% | 0.00 |
| Robin Joseph Pinto | Promoter | 0.18% | 0.00 |
| Neha Saldanha | Promoter | 0.01% | 0.00 |
| Hdfc Mutual Fund - Hdfc Nifty 200 Momentum 30 Inde | DII | Exited | — |
| Invesco India Large & Mid Cap Fund | DII | Exited | — |
| Uti-Healthcare Fund | DII | Exited | — |
| Bandhan Balanced Advantage Fund | DII | Exited | — |
Promoters held 46.61% of Glenmark Pharmaceuticals at the end of the Jun 2026 quarter, up 0.01 percentage points from 46.60% a year earlier.
In the Jun 2026 quarter, foreign institutional investors (FIIs) held 20.91% (up 0.54 percentage points from 20.37% a quarter earlier) and domestic institutions (DIIs) held 18.58% (down 0.68 percentage points from 19.26% a quarter earlier).
No. The Jun 2026 filing shows no pledged promoter shares.
Glenmark Pharmaceuticals had 2,11,396 shareholders at the end of the Jun 2026 quarter, against 1,90,190 a year earlier.
Hdfc Mutual Fund - Hdfc Mid-Cap Fund (DII) held 6.18% at the end of the Jun 2026 quarter, the largest named holding outside the promoter group.